A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1868-7083
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients ; volume:11 ; number:1 ; day:20 ; month:2 ; year:2019 ; pages:1-11 ; date:12.2019
Clinical epigenetics ; 11, Heft 1 (20.2.2019), 1-11, 12.2019
- Urheber
-
Pineda, Begoña
Diaz-Lagares, Angel
Pérez-Fidalgo, José Alejandro
Burgués, Octavio
González-Barrallo, Inés
Crujeiras, Ana B.
Sandoval, Juan
Esteller, Manel
Lluch, Ana
Eroles, Pilar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13148-019-0626-0
- URN
-
urn:nbn:de:101:1-2019032016092131558043
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pineda, Begoña
- Diaz-Lagares, Angel
- Pérez-Fidalgo, José Alejandro
- Burgués, Octavio
- González-Barrallo, Inés
- Crujeiras, Ana B.
- Sandoval, Juan
- Esteller, Manel
- Lluch, Ana
- Eroles, Pilar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress
Metastatic Triple-Negative Breast Cancer
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress
Metastatic Triple-Negative Breast Cancer
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress
Metastatic Triple-Negative Breast Cancer